Japanese Encephalitis: the Virus and Vaccines

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2013 Oct 29

PMID 24161909

Citations 118

Authors

Sang-Im Yun

Young-Min Lee

Affiliations

Soon will be listed here.

Abstract

Japanese encephalitis (JE) is an infectious disease of the central nervous system caused by Japanese encephalitis virus (JEV), a zoonotic mosquito-borne flavivirus. JEV is prevalent in much of Asia and the Western Pacific, with over 4 billion people living at risk of infection. In the absence of antiviral intervention, vaccination is the only strategy to develop long-term sustainable protection against JEV infection. Over the past half-century, a mouse brain-derived inactivated vaccine has been used internationally for active immunization. To date, however, JEV is still a clinically important, emerging, and re-emerging human pathogen of global significance. In recent years, production of the mouse brain-derived vaccine has been discontinued, but 3 new cell culture-derived vaccines are available in various parts of the world. Here we review current aspects of JEV biology, summarize the 4 types of JEV vaccine, and discuss the potential of an infectious JEV cDNA technology for future vaccine development.

Citing Articles

Climate change's impact on the nervous system: A review study.

Sadeghi M, Ghannadi P, Lotfi A, Ashayeri H Health Promot Perspect. 2025; 14(4):336-342.

PMID: 40041730 PMC: 11873770. DOI: 10.34172/hpp.43089.

Partial protective efficacy of the current licensed Japanese encephalitis live vaccine against the emerging genotype I Japanese encephalitis virus isolated from sheep.

Zhang H, Zhang Y, Li D, Zheng J, Zhang J, Li Z Front Immunol. 2025; 16:1513261.

PMID: 40018033 PMC: 11865068. DOI: 10.3389/fimmu.2025.1513261.

Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.

Baric T, Reneer Z Viruses. 2025; 17(1).

PMID: 39861790 PMC: 11769264. DOI: 10.3390/v17010001.

Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SA-14-2.

Song B, Frank J, Yun S, Julander J, Mason J, Polejaeva I Int J Mol Sci. 2025; 26(1.

PMID: 39796052 PMC: 11720029. DOI: 10.3390/ijms26010195.

Key virulence factors responsible for differences in pathogenicity between clinically proven live-attenuated Japanese encephalitis vaccine SA14-14-2 and its pre-attenuated highly virulent parent SA14.

Song B, Yun S, Goldhardt J, Kim J, Lee Y PLoS Pathog. 2025; 21(1):e1012844.

PMID: 39775684 PMC: 11741592. DOI: 10.1371/journal.ppat.1012844.

References

Morrison J, Aguirre S, Fernandez-Sesma A . Innate immunity evasion by Dengue virus. Viruses. 2012; 4(3):397-413. PMC: 3347034. DOI: 10.3390/v4030397. View

Yu Y . Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine. 2010; 28(21):3635-41. DOI: 10.1016/j.vaccine.2010.02.105. View

Kobayashi Y, Hasegawa H, Oyama T, Tamai T, Kusaba T . Antigenic analysis of Japanese encephalitis virus by using monoclonal antibodies. Infect Immun. 1984; 44(1):117-23. PMC: 263479. DOI: 10.1128/iai.44.1.117-123.1984. View

Kummerer B, Rice C . Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J Virol. 2002; 76(10):4773-84. PMC: 136122. DOI: 10.1128/jvi.76.10.4773-4784.2002. View

Seif S, Morita K, Matsuo S, Hasebe F, Igarashi A . Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system. Vaccine. 1995; 13(16):1515-21. DOI: 10.1016/0264-410x(95)00097-k. View

Chu J, Leong P, Ng M . Analysis of the endocytic pathway mediating the infectious entry of mosquito-borne flavivirus West Nile into Aedes albopictus mosquito (C6/36) cells. Virology. 2006; 349(2):463-75. DOI: 10.1016/j.virol.2006.01.022. View

Plesner , Herning . Neurological complications to vaccination against Japanese encephalitis. Eur J Neurol. 1999; 5(5):479-485. DOI: 10.1046/j.1468-1331.1998.550479.x. View

Tsai T, Yu Y, Jia L, Putvatana R, Zhang R, Wang S . Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules. J Infect Dis. 1998; 177(1):221-3. DOI: 10.1086/517358. View

Ye J, Zhu B, Fu Z, Chen H, Cao S . Immune evasion strategies of flaviviruses. Vaccine. 2012; 31(3):461-71. DOI: 10.1016/j.vaccine.2012.11.015. View

10.

Westaway E, Mackenzie J, Khromykh A . Kunjin RNA replication and applications of Kunjin replicons. Adv Virus Res. 2003; 59:99-140. DOI: 10.1016/s0065-3527(03)59004-2. View

11.

Geiss B, Stahla H, Hannah A, Gari A, Keenan S . Focus on flaviviruses: current and future drug targets. Future Med Chem. 2010; 1(2):327-44. PMC: 2822355. DOI: 10.4155/fmc.09.27. View

12.

Mukhopadhyay S, Kim B, Chipman P, Rossmann M, Kuhn R . Structure of West Nile virus. Science. 2003; 302(5643):248. DOI: 10.1126/science.1089316. View

13.

Fischer M, Lindsey N, Staples J, Hills S . Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-1):1-27. View

14.

Bressanelli S, Stiasny K, Allison S, Stura E, Duquerroy S, Lescar J . Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 2004; 23(4):728-38. PMC: 380989. DOI: 10.1038/sj.emboj.7600064. View

15.

WESTAWAY E, Mackenzie J, Khromykh A . Replication and gene function in Kunjin virus. Curr Top Microbiol Immunol. 2002; 267:323-51. DOI: 10.1007/978-3-642-59403-8_16. View

16.

Kuhn R, Zhang W, Rossmann M, Pletnev S, Corver J, Lenches E . Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002; 108(5):717-25. PMC: 4152842. DOI: 10.1016/s0092-8674(02)00660-8. View

17.

Chambers T, Grakoui A, Rice C . Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol. 1991; 65(11):6042-50. PMC: 250270. DOI: 10.1128/JVI.65.11.6042-6050.1991. View

18.

Kim J, Yun S, Song B, Hahn Y, Lee C, Oh H . A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. J Virol. 2008; 82(16):7846-62. PMC: 2519568. DOI: 10.1128/JVI.00789-08. View

19.

Sampath A, Padmanabhan R . Molecular targets for flavivirus drug discovery. Antiviral Res. 2008; 81(1):6-15. PMC: 2647018. DOI: 10.1016/j.antiviral.2008.08.004. View

20.

Yu I, Zhang W, Holdaway H, Li L, Kostyuchenko V, Chipman P . Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008; 319(5871):1834-7. DOI: 10.1126/science.1153264. View